Inhibitory effect of evodiamine alone and in combination with rosiglitazone on in vitro adipocyte differentiation and in vivo obesity related to diabetes

International Journal of Obesity

Volumn 34, Issue 2, 2010, Pages 250-260

  Bak, E J ^a   Park, H G ^a,b   Kim, J M ^a,b,c   Yoo, Y J ^a,c   Cha, J H ^a,c  

^a Yonsei University College of Dentistry   (South Korea)

^b Hanyang University College of Medicine   (South Korea)

^c Yonsei University   (South Korea)

Author keywords

Adipocyte differentiation; Diabetes; Evodaimine; Rosiglitazone

Indexed keywords

EVODIAMINE; GLUCOSE; GLYCOGEN; INSULIN; ROSIGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; ADIPOQ PROTEIN, MOUSE; ANTIDIABETIC AGENT; FAT INTAKE; GLUCOSE BLOOD LEVEL; PLANT EXTRACT; QUINAZOLINE DERIVATIVE;

ADIPOCYTE; ADIPOGENESIS; ADIPOSE TISSUE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLOOD; CELL DIFFERENTIATION; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID STORAGE; LIVER; LIVER INJURY; LIVER TOXICITY; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WEIGHT GAIN; ANIMAL; C57BL MOUSE; CELL LINE; DRUG COMBINATION; DRUG EFFECTS; FAT INTAKE; METABOLISM;

ADIPOCYTES; ADIPONECTIN; ADIPOSE TISSUE; ANIMALS; BLOOD GLUCOSE; CELL DIFFERENTIATION; CELL LINE; DIETARY FATS; DRUG THERAPY, COMBINATION; HYPOGLYCEMIC AGENTS; INSULIN; LIVER; MICE; MICE, INBRED C57BL; OBESITY; PLANT EXTRACTS; QUINAZOLINES; THIAZOLIDINEDIONES; WEIGHT GAIN;

MUS;

EID: 76749097555     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2009.223     Document Type: Article

References (50)

1. Feve B. Adipogenesis: cellular and molecular aspects. Best Pract Res Clin Endocrinol Metab 2005; 19: 483-499.
2. Laviola L, Perrini S, Cignarelli A, Giorgino F. Insulin signalling in human adipose tissue. Arch Physiol Biochem 2006; 112: 82-88.
3. Moitra J, Mason MM, Olive M, Krylov D, Gavrilova O, Marcus-Samuels B et al. Life without white fat: a transgenic mouse. Genes Dev 1998; 12: 3168-3181.
4. Shimomura I, Hammer RE, Richardson JA, Ikemoto S, Bashmakov Y, Goldstein JL et al. Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy. Genes Dev 1998; 12: 3182-3194.
5. Shimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein JL. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 1999; 401: 73-76.
6. Iwaki M, Matsuda M, Maeda N, Funahashi T, Matsuzawa Y, Makishima M et al. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 2003; 52: 1655-1663.
7. Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med 2002; 346: 570-578.
8. Reznikoff CA, Brankow DW, Heidelberger C. Establishment and characterization of a cloned line of C3 H mouse embryo cells sensitive to postconfluence inhibition of division. Cancer Res 1973; 33: 3231-3238.
9. Pinney DF, Emerson Jr CP. 10T1/2 cells: an in vitro model for molecular genetic analysis of mesodermal determination and differentiation. Environ Health Perspect 1989; 80: 221-227.
10. Bowers RR, Kim JW, Otto TC, Lane MD. Stable stem cell commitment to the adipocyte lineage by inhibition of DNA methylation: role of the BMP-4 gene. Proc Natl Acad Sci USA 2006; 103: 13022-13027.
11. Green H, Kehinde O. Sublines of mouse 3T3 cells that accumulate lipid. cell 1974; 1: 113-115.
12. Green H, Kehinde O. An established preadipose cell line and its differentiation in culture. II. Factors affecting the adipose conversion. Cell 1975; 5: 19-27.
13. Green H, Kehinde O. Spontaneous heritable changes leading to increased adipose conversion in 3T3 cells. Cell 1976; 7: 105-113.
14. Gurnell M. Peroxisome proliferator-activated receptor gamma and the regulation of adipocyte function: lessons from human genetic studies. Best Pract Res Clin Endocrinol Metab 2005; 19: 501-523.
15. Takasawa K, Kubota N, Terauchi Y, Kadowaki T. Impact of increased PPARgamma activity in adipocytes in vivo on adiposity, insulin sensitivity and the effects of rosiglitazone treatment. Endocr J 2008; 55: 767-776.
16. Moller DE. New drug targets for type 2 diabetes and the metabolic syndrome. Nature 2001; 414: 821-827.
17. Tiikkainen M, Hakkinen AM, Korsheninnikova E, Nyman T, Makimattila S, Yki-Jarvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004; 53: 2169-2176.
18. Boden G, Homko C, Mozzoli M, Showe LC, Nichols C, Cheung P. Thiazolidinediones upregulate fatty acid uptake and oxidation in adipose tissue of diabetic patients. Diabetes 2005; 54: 880-885.
19. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. 7 October 2003. Circulation 2003; 108: 2941-2948.
20. Sood V, Colleran K, Burge MR. Thiazolidinediones: a comparative review of approved uses. Diabetes Technol Ther 2000; 2: 429-440.
21. Lebovitz HE. Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metab Res Rev 2002; 18 (Suppl 2): S23-S29.
22. Turmelle YP, Shikapwashya O, Tu S, Hruz PW, Yan Q, Rudnick DA. Rosiglitazone inhibits mouse liver regeneration. FASEB J 2006; 20: 2609-2611.
23. Tang W, Eisenbrand G. Evodia rutaecarpa (Juss) Benth, in Chinese Drugs of Plant Origin. Springer-Verlag: Berlin 1992; 509-514.
24. Yu ZK, Wright JT, Hausman GJ. Preadipocyte recruitment in stromal vascular cultures after depletion of committed preadipo-cytes by immunocytotoxicity. Obes Res 1997; 5: 9-15.
25. Fei XF, Wang BX, Li TJ, Tashiro S, Minami M, Xing DJ et al. Evodiamine, a constituent of Evodiae Fructus, induces anti-proliferating effects in tumor cells. Cancer Sci 2003; 94: 92-98.
26. Wang T, Wang Y, Kontani Y, Kobayashi Y, Sato Y, Mori N et al. Evodiamine improves diet-induced obesity in a uncoupling protein-1-independent manner: involvement of antiadipogenic mechanism and extracellularly regulated kinase/mitogen-acti-vated protein kinase signaling. Endocrinology 2008; 149: 358-366.
27. Student AK, Hsu RY, Lane MD. Induction of fatty acid synthetase synthesis in differentiating 3T3-L1 preadipocytes. J Biol Chem 1980; 255: 4745-4750.
28. Tang QQ, Otto TC, Lane MD. Commitment of C3H10T1/2 pluripotent stem cells to the adipocyte lineage. Proc Natl Acad Sci USA 2004; 101: 9607-9611.
29. Lee JS, Suh JM, Park HG, Bak EJ, Yoo YJ, Cha JH. Heparin-binding epidermal growth factor-like growth factor inhibits adipocyte differentiation at commitment and early induction stages. Differentiation 2008; 76: 478-487.
30. Madsen L, Petersen RK, Sorensen MB, Jorgensen C, Hallenborg P, Pridal L et al. Adipocyte differentiation of 3T3-L1 preadipocytes is dependent on lipoxygenase activity during the initial stages of the differentiation process. Biochem J 2003; 375: 539-549.
31. Nugent C, Prins JB, Whitehead JP, Savage D, Wentworth JM, Chatterjee VK et al. Potentiation of glucose uptake in 3T3-L1 adipocytes by PPAR gamma agonists is maintained in cells expressing a PPAR gamma dominant-negative mutant: evidence for selectivity in the downstream responses to PPAR gamma activation. Mol Endocrinol 2001; 15: 1729-1738.
32. Wilson-Fritch L, Burkart A, Bell G, Mendelson K, Leszyk J, Nicoloro S et al. Mitochondrial biogenesis and remodeling during adipogenesis and in response to the insulin sensitizer rosiglita-zone. Mol Cell Biol 2003; 23: 1085-1094.
33. Hong JH, Hwang ES, McManus MT, Amsterdam A, Tian Y, Kalmukova R et al. TAZ, a transcriptional modulator of mesen-chymal stem cell differentiation. Science 2005; 309: 1074-1078.
34. Hutley LJ, Newell FM, Joyner JM, Suchting SJ, Herington AC, Cameron DP et al. Effects of rosiglitazone and linoleic acid on human preadipocyte differentiation. Eur J Clin Invest 2003; 33: 574-581.
35. Ahrens M, Ankenbauer T, Schroder D, Hollnagel A, Mayer H, Gross G. Expression of human bone morphogenetic proteins-2 or-4 in murine mesenchymal progenitor C3H10T1/2 cells induces differentiation into distinct mesenchymal cell lineages. DNA Cell Biol 1993; 12: 871-880.
36. Tack CJ, Smits P. Thiazolidinedione derivatives in type 2 diabetes mellitus. Neth J Med 2006; 64: 166-174.
37. Kobayashi Y, Nakano Y, Kizaki M, Hoshikuma K, Yokoo Y, Kamiya T. Capsaicin-like anti-obese activities of evodiamine from fruits of Evodia rutaecarpa, a vanilloid receptor agonist. Planta Med 2001; 67: 628-633.
38. Chen D, Zhao M, Mundy GR. Bone morphogenetic proteins. Growth Factors 2004; 22: 233-241.
39. Bowers RR, Lane MD. A role for bone morphogenetic protein-4 in adipocyte development. Cell Cycle 2007; 6: 385-389.
40. Reddi AH. Bone morphogenetic proteins: an unconventional approach to isolation of first mammalian morphogens. Cytokine Growth Factor Rev 1997; 8: 11-20.
41. Huang H, Song TJ, Li X, Hu L, He Q, Liu M et al. BMP signaling pathway is required for commitment of C3H10T1/2 pluripotent stem cells to the adipocyte lineage. Proc Natl Acad Sci USA 2009; 106: 12670-12675.
42. Caplan AI. Mesenchymal stem cells. J Orthop Res 1991; 9: 641-650.
43. Young HE, Mancini ML, Wright RP, Smith JC, Black Jr AC, Reagan CR et al. Mesenchymal stem cells reside within the connective tissues of many organs. Dev Dyn 1995; 202: 137-144.
44. Shepherd PR, Gnudi L, Tozzo E, Yang H, Leach F, Kahn BB. Adipose cell hyperplasia and enhanced glucose disposal in transgenic mice overexpressing GLUT4 selectively in adipose tissue. J Biol Chem 1993; 268: 22243-22246.
45. Sorisky A. From preadipocyte to adipocyte: differentiation-directed signals of insulin from the cell surface to the nucleus. Crit Rev Clin Lab Sci 1999; 36: 1-34.
46. Tanabe Y, Koga M, Saito M, Matsunaga Y, Nakayama K. Inhibition of adipocyte differentiation by mechanical stretching through ERK-mediated downregulation of PPARgamma2. J Cell Sci 2004; 117: 3605-3614.
47. Jo J, Gavrilova O, Pack S, Jou W, Mullen S, Sumner AE et al. Hypertrophy and/or hyperplasia: dynamics of adipose tissue growth. PLoS Comput Biol 2009; 5: e1000324.
48. Ikeda D, Sakaue S, Kamigaki M, Ohira H, Itoh N, Ohtsuka Y et al. Knockdown of macrophage migration inhibitory factor disrupts adipogenesis in 3T3-L1 cells. Endocrinology 2008; 149: 6037-6042.
49. Chaput E, Saladin R, Silvestre M, Edgar AD. Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. Biochem Biophys Res Commun 2000; 271: 445-450.
50. Mittra S, Sangle G, Tandon R, Sharma S, Roy S, Khanna V et al. Increase in weight induced by muraglitazar, a dual PPARalpha/ gamma agonist, in db/db mice: adipogenesis/or oedema? Br J Pharmacol 2007; 150: 480-487.